As go drug sales (and prices), so go the fortunes of drug distributors like Pennsylvania-based AmerisourceBergen, which acts as a middleman, delivering medicines from manufacturers to pharmacies and hospitals. AmerisourceBergen’s revenues climbed 9.7% in 2018 thanks to overall market growth and brisk sales of expensive cancer drugs. The company’s acquisition of wholesaler H.D. Smith—completed in January of 2018—and the performance of its joint venture with Profarma in Brazil also boosted revenues, as did AmerisourceBergen’s veterinary medicine business. The company is facing issues involving its drug compounding subsidiary PharMEDium and, like its competitors, AmerisourceBergen is under scrutiny for its alleged role in the nation’s opioid crisis.
Looking for leads, investment insights, or competitive intelligence?
News about AmerisourceBergen
Bold acquisitions and global expansion lifted Amerisource's ranking to number 12 on Fortune 500
Steve Collis predicts new era of where drug prices are going to come down.
Amazon and CVS are putting on the pressure.
Sparking a selloff in the shares of a host of health care-related companies.
Corporate governance matters, too.